The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | CAR T-cells: targeting BCMA
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, Philadelphia, PA, speaks about his excitement over the CRB-401 study (NCT02658929), which uses anti-BCMA CAR T-cell agent idecabtagene vicleucel (formerly bb2121) for refractory multiple myeloma (MM). BCMA targeting represents a new area for CAR T-cells, and Dr Grupp emphasizes the importance of these positive findings in MM and other hematological malignancies.
